Owing to this negative feedback response of PCSK9 on the LDL cholesterol-lowering effect of LDLR, PCSK9 inhibition has been suggested as an alternative strategy for the treatment of hypercholesterolemia and related-chronic diseases since its discovery in 2003 [6,7]. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.